June 17, 2022 7:26am

And my hands DON’T shake as I review the sector’s low and its geography

It’s just a game of cycles

Pre-open indications: 3 Positive Indications, 3 Negative Indications, Puff/Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

The 7:30 A.M., ET edition


Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are UP +0.65% (+195 points), S&P futures are UP +0.85% (+31 points) and NASDAQ futures are UP +1.20% (+134 points) early in the pre-open – so far,


Stock futures rose Friday

European stocks were rebounding

Asia-Pacific stocks struggled for direction



The Dow closed DOWN -741.46 points (-2.42%); the S&P closed DOWN -123.22 points (-3.25%) while the Nasdaq closed DOWN -453.06 points (-4.08%).

The Nasdaq has been hit harder, and is down 6.1% for the week.

“This week was brutal. ... Let me tell you, we’re in a recession,” Wharton Business School professor Jeremy Siegel said Thursday on CNBC’s “Closing Bell: Overtime.” “It’s a mild recession. It’s not an official recession by the NBER, certainly not yet, but this first half is negative GDP growth, and it’s ending on a slide.” <CNBC>

Economic Data Docket: relatively light day for economic data, with industrial production data for May due out before the opening bell.


RegMed Investors’ (RMi) closing bell: “the rise and fall of the cell and gene therapy space. Management and directors NEED to start “funding/investing” their own $$ to position upside by personal buying commitment” … https://www.regmedinvestors.com/articles/12476

Ebb and flow –

Q2/22 –

June – 5 positive and 7 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Negative Indications:

Alnylam Pharmaceuticals (ALNY) closed down -$0.63 to $134.82 <52-week low of $117.58> with a negative -0.66 or -0.49%,

Chinook Therapeutics (KDNY) closed down -.41 to $16.42 <52-week low of $10.48> with a negative -$0.83 or -5.05% pre-open indication,

BioLife Solutions (BLFS) closed down -$0.84 to $13.26 <52-week low of $10.40> with a negative -$0.24 or -1.81% pre-open indication


Positive indications ….

Verve Therapeutics (VERV) closed down -$1.15 to $11.14 <52-week low of $10.70> with a positive +0.46 or +4.13% pre-open indication,

CRISPR Therapeutics (CRSP) closed up +$1.987 to $<52-low of $42.52> with a positive +0.76 or +1.18% pre-open indication,

Sage Therapeutics (SAGE) closed down -$1.21 to $31.26 <52-week low of $27.36> with a positive +$0.64 or +2.04%,

Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed down -$0.20 to $4.30 with 1,254 shares traded after Wednesday’s flat with 0 shares traded, Tuesday’s -$0.40 to $4.50 with 100 shares traded, Monday’s +$ 0.15 with 100 shares traded and last Friday’s +$0.065 with 295 shares traded.

WARNING:  Earnings reported a VERY SAD picture of a company’s status without U.S investors and reliance on non-U.S. Chinese investors. Another PPM -private placement – this one for $5.1 M without a price per share notification. Also, the terminal death lawsuit just got settled (4/28) for $6 M with a PPM – a preferred convertible debt financing.

BSTG filed a new 8-K re Harvard BIOSCIENCE  (HBIO) and in lieu of cash payment < https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=116769338&type=HTML&formType=8-K&dateFiled=2022-06-13&cik=0001563665&CK=1563665&symbol=0001563665&companyName=Biostage >

BSTG seems to always finagling a finagle and NOTHING is CLEAN and STRAIGHTFORWARD.

 is it the ONLY avenue to finance utilizing non-U.S. Chinese investors?

·         So, Has BSTG filed its Annual Report to the FDA, isn’t it a “Material Fact”?

·         Is yet ANOTHER financing on-going of 5+M shares being prepared to be sold?


The BOTTOM LINE: The cell and gene therapy suffered significant losses last Thursday, gained some altitude on Wednesday following Tuesday and Monday’s negative sessions; last Friday and the previous Thursday had negative closes.

Investors may want to at least consider taking partial profits – when they can; we are approaching earnings season, no sooner did we finish than we start again.

I STILL haven’t heard the bugle sound of a sustainable advance or rally … rising rates and slowing economic growth are not a supportive environment for investors.

Again, as have I written (repeatedly), “There's a battle in the cell and gene therapy sector between which or what breaks first: share pricing resistance or tumbling into yet another downturn as fear remains beneath the strength of any positive close” …

This continuing state of volatility confirms fears that I have been expressing in these daily and weekly posts.

I have NOT seen ANY step-up of declining company investments by ANY CEOs and their management teams – WHY NOT?

I try to keep it simple … and short!

There is VALUE out there however, it’s about playing or betting the timing of the sector.

We are left with choosing to hang on to “our” portfolio position as it is a given that the sector shifts from fierce, sudden sell-offs to gaining altitude or ascending not to its value but, better than it was.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.